Product ID: SQMIG35H2061
Report ID:
SQMIG35H2061 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
128 |
Figures:
77
Companies are getting FDA permission for stem cell treatment for a variety of disorders and infections. For example, in September 2020, the FDA granted Stemedica Cell Technologies, Inc. Investigational New Drug permission to undertake phase II studies of intravenously delivered allogeneic MSCs in covid-19 patients. Ischemic-tolerant MSCs have various characteristics that make them an appealing potential biological treatment for COVID-19, including immunomodulatory effects, limited immunogenicity, and the ability to inhibit excessive pro-inflammatory responses.
Cell Therapy Market Top Players' Company Profiles
Cell Therapy Market
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONCell Therapy Market size was valued at USD 18.92 billion in 2019 and is poised to grow from USD 21.6 billion in 2023 to USD 71.07 billion by 2031, growing at a CAGR of 14.15% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35H2061